T-cell malignancies with anti-CD19 chimeric antigen receptor T-cell therapy

被引：1
|
作者：
Martin, Lisa J. [1 ]
Whitmore, James B. [1 ]
Shen, Rhine R. [1 ]
Neumann, Frank [1 ]
机构：
[1] Kite A Gilead Co, 2400 Broadway, Santa Monica, CA 90404 USA
来源：
BLOOD ADVANCES | 2024年 / 8卷 / 15期
关键词：
D O I：
10.1182/bloodadvances.2024013248
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：4144 / 4148
页数：5
相关论文
共 50 条
  • [21] Biomarkers of Response to Anti-CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy in Patients with Chronic Lymphocytic Leukemia
    Fraietta, Joseph A.
    Lacey, Simon F.
    Wilcox, Nicholas S.
    Bedoya, Felipe
    Chen, Fang
    Orlando, Elena
    Brogdon, Jennifer L.
    Hwang, Wei-Ting
    Frey, Noelle
    Young, Regina M.
    Pequignot, Edward
    Ambrose, David E.
    Levine, Bruce L.
    Bitter, Hans
    Porter, David L.
    Xu, Jun
    June, Carl H.
    Melenhorst, Jan Joseph
    BLOOD, 2016, 128 (22)
  • [22] Chimeric antigen receptor T-cell therapy
    Burge, Cale
    Vanguru, Vinay
    Ho, Phoebe Joy
    AUSTRALIAN PRESCRIBER, 2023, 46 (02) : 36 - 39
  • [23] Chimeric Antigen Receptor T-Cell Therapy
    Ogba, Ndiya
    Arwood, Nicole M.
    Bartlett, Nancy L.
    Bloom, Mara
    Brown, Patrick
    Brown, Christine
    Budde, Elizabeth Lihua
    Carlson, Robert
    Farnia, Stephanie
    Fry, Terry J.
    Garber, Morgan
    Gardner, Rebecca A.
    Gurschick, Lauren
    Kropf, Patricia
    Reitan, Jeff J.
    Sauter, Craig
    Shah, Bijal
    Shpall, Elizabeth J.
    Rosen, Steven T.
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2018, 16 (09): : 1093 - 1106
  • [24] Cardiotoxicity Associated with Anti-CD19 Chimeric Antigen Receptor T-Cell (CAR-T) Therapy: Recognition, Risk Factors, and Management
    Burns, Ethan A.
    Gentille, Cesar
    Trachtenberg, Barry
    Pingali, Sai Ravi
    Anand, Kartik
    DISEASES, 2021, 9 (01)
  • [25] Chimeric Antigen Receptor T-Cell Therapy
    Rasheed, Azgar Abdul
    Koyyala, Venkata Pradeep Babu
    INDIAN JOURNAL OF MEDICAL AND PAEDIATRIC ONCOLOGY, 2021, 42 (01) : 89 - 92
  • [26] Excessive activated T-cell proliferation after anti-CD19 CAR T-cell therapy
    Zhang, Wen-ying
    Liu, Yang
    Wang, Yao
    Nie, Jing
    Guo, Ye-lei
    Wang, Chun-meng
    Dai, Han-ren
    Yang, Qing-ming
    Wu, Zhi-qiang
    Han, Wei-dong
    GENE THERAPY, 2018, 25 (03) : 198 - 204
  • [27] Good Tolerance and Durable Remission for Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy in Refractory/Relapsed Mantle Cell Lymphoma
    Ye, Shiguang
    Zhou, Lili
    Li, Shaoguang
    Li, Ping
    Liang, Aibin
    BLOOD, 2019, 134
  • [28] Excessive activated T-cell proliferation after anti-CD19 CAR T-cell therapy
    Wen-ying Zhang
    Yang Liu
    Yao Wang
    Jing Nie
    Ye-lei Guo
    Chun-meng Wang
    Han-ren Dai
    Qing-ming Yang
    Zhi-qiang Wu
    Wei-dong Han
    Gene Therapy, 2018, 25 : 198 - 204
  • [29] Clinical development of anti-CD19 chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma
    Makita, Shinichi
    Yoshimura, Kiyoshi
    Tobinai, Kensei
    CANCER SCIENCE, 2017, 108 (06) : 1109 - 1118
  • [30] Overcoming resistance to anti-CD19 CAR T-cell therapy in B-cell malignancies
    Yang, Xingcheng
    Wei, Jia
    Zhou, Jianfeng
    HEMATOLOGICAL ONCOLOGY, 2022, 40 (05) : 821 - 834
12345